United Kingdom · Question · Written question
UIN 174167
Respiratory Syncytial Virus: Vaccination
Introduced
27 March 2023
Last action
3 April 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
3 April 2023
Summary
To ask the Secretary of State for Health and Social Care, with reference to the Joint Committee on Vaccination and Immunisation (JCVI) recommendation to work towards replacing palivizumab with nirsevimab in 2022, what steps his Department plans to take to
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
27 March 2023
Written question
To ask the Secretary of State for Health and Social Care, with reference to the Joint Committee on Vaccination and Immunisation (JCVI) recommendation to work towards replacing palivizumab with nirsevimab in 2022, what steps his Department plans to take to
Source: Commons
3 April 2023
Answer
The Joint Committee on Vaccination and Immunisation (JCVI) has advised that the current respiratory syncytial virus (RSV) monoclonal antibody, palivizumab, should be replaced by nirsevimab for the existing, targeted cohort. The Department, the UK Health S...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-03-27/174167
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1608043
- uk · wq-1608043 · source updated 3 April 2023